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ABSTRACTSBetween the SCP and SpR groups therewas no difference in (1) mean intra-
operative re-transfusion (598ml vs 636ml p¼0.44), (2) mean post-opera-
tive haemoglobin drop (2.32g/dl vs 2.29g/dl, p¼0.92), and (3) mean
operating time (137.9min vs 141.7min, p¼0.57).
Conclusions: As an assistant, there is no difference between the SCP and
SpR. Our data supports using the SCP as an experienced ﬁrst assistant to
the experienced SpR for training.
0723: SURGICAL OUTCOMES OF NEPHRON SPARING SURGERY FOR
RENAL TUMOURS
Anna Mainwaring, Ninaad Awsare, Pradeep Bose, Neil Fenn, Jonathan
Featherstone. Morriston Hospital, Swansea, UK
Aim: Nephron sparing surgery (NSS) is increasingly being performed to
treat renal tumours. We reviewed our surgical outcomes following partial
nephrectomy.
Methods:A retrospective reviewof 51 consecutive patients (median age 59
years) undergoing NSS for renal tumours between 1999 and 2011. Indica-
tions for NSSwere absolute (n¼14), relative (n¼16) or elective (n¼21). Data
collected included peri-operative, histological, disease-free and overall
survival data. Complicationswere recorded using the Clavien classiﬁcation.
Results: Most procedures were performed open (n¼46). More recently
selected cases have been performed laparoscopically (n¼5). There were no
peri-operativedeathsandnopatients required renaldialysis. Sixteenpatients
(31%) had post-operative complications. Of these, 8 were Grade 1, 5 were
Grade2 and3wereGrade 3aaccording to theClavien classiﬁcation.Histology
conﬁrmed 37(73%) tumours were malignant and 14(27%) were benign.
During follow up there were no local recurrences, but 1 patient (3%) devel-
opedmetastatic disease. The overall survival rate at amedian follow up of 31
monthswas 92%with only one death attributable tometastatic renal cancer.
Conclusion: NSS for renal tumours is safe with an acceptable peri-oper-
ative morbidity rate. Preservation of renal function and low recurrence
rates conﬁrm it is an effective treatment option.
0755: CAN URINE CYTOLOGY BE SAFELY OMITTED FROM ROUTINE
WORK-UP FOR HAEMATURIA?
Eleni Anastasiadis 2, Dhili Arul 1, Kara Bruce-Hickman 1, Sudhanshu
Chitale 1, M. Ghei 1, Barry Maraj 1. 1Whittington Health, London, UK; 2 St
George's Healthcare Trust, London, UK
Introduction / Aim: Urine cytology has traditionally been part of routine
work-up for patients with haematuria but provided relatively limited
diagnostic yield at a signiﬁcant cost. We audited our practice in the local
setting to assess the value of urine cytology and the implications of
deleting it from the investigative pathway.
Method: Clinical data for 191 patients referred for urine cytological
examination over a period of 3 months (July – September 2010) was
collected from the hospital database.
Results: Haematuria was the presentation in 138 (73%) of these requests.
69% (95/138) were from Urologists. Of the 138, 77% were reported normal,
4% revealed atypical cells, 3% had malignant cells, 8% had appearances
indicative of inﬂammatory pathology and 8% were unsuitable for analysis.
Positive yield was < 10%. Of the 7% (9/138) with proven urothelial cancer
(only of bladder in this series), cytology was normal in 44%, atypical in 11%,
and malignant in 33%, highlighting that cytology would have missed
cancer in >50% of haematuria cases.
Conclusion: Urine cytology has very poor sensitivity for diagnosing uro-
thelial cancer, and the cost and effort to conduct this investigation does not
justify its use in the routine work-up of patients with haematuria.
0769: INCIDENTAL SYNCHRONOUS PRIMARY TUMOURS DETECTED
DURING A MODIFIED MRI PROSTATE PROTOCOL
Paul Hughes, Rajesh Nair, Tim Larner. Brighton and Sussex University
Hospitals NHS Trust, Brighton, UK
Introduction: Magnetic resonance imaging (MRI) is the cross-sectional
imaging modality of choice in staging prostate cancer. Standard protocol
for prostate MRI is limited to the pelvis. We describe beneﬁts of extended
MRI protocols in identifying incidental synchronous primary lesions,
which potentially inﬂuence prostate cancer management.
Patients & Methods: A retrospective single-center review of 464 patients
(median age 68, range 47-82 years) with a diagnosis of prostate cancerbetween January 2008 and December 2011 was performed. Outcomes
were reviewed in patients that underwent extended-MRI staging inwhom
synchronous abdominal and pelvic masses were identiﬁed.
Results: Eight patients had synchronous lesions identiﬁed: one adrenal
mass, one rectal cancer, two bladder cancers and four renal masses. The
adrenal mass was a non-functioning adenoma and one renal mass was
identiﬁed as a simple cyst. The remaining six cases (1.3%) had conﬁrmed
synchronous malignancies. In two patients this did not inﬂuence prostate
cancer management. The patients with rectal cancer and muscle invasive
bladder cancer would have been identiﬁed with conventional protocols.
The two patients with advanced renal malignancy were identiﬁed due to
extended MRI.
Conclusion: Signiﬁcant renal lesions were identiﬁed on extended-MRI
staging protocols for prostate cancer. These synchronous malignancies
potentially inﬂuence prostate cancer management.
0772: THE ROLE OF CONTRAST ENHANCED ULTRASOUND IN THE
ASSESSMENT OF COMPLEX OR EQUIVOCAL RENAL LESIONS
Paul Hughes, Rajesh Nair, Emma Simpson, Tim Larner. Brighton and Sussex
University Hospitals, Brighton, UK
Introduction: Contrast enhanced computed tomography (CECT) remains
the standard imaging modality for renal lesion characterisation. Circum-
stances however, exist where diagnostic uncertainty remains. Contrast
enhanced ultrasound (CEUS) is a safe, affordable, non-ionising adjunct in
the assessment of difﬁcult renal lesions. We describe our experience with
this emerging radiological technique.
Material andMethods:A single-centre retrospective reviewof 21 patients,
median age of 68 years (range 35-89 years) with equivocal renal lesions
was performed. All patients underwent CEUS using sonovuemicro-bubbles
between November 2010 and August 2011. Renal lesion enhancement,
clinical outcomes and histological correlation were analysed.
Results: In six patients with complex cystic renal lesions, three demon-
strated concerning enhancement. In thirteen cases with equivocal solid
lesions, nine were suggestive of renal cell carcinoma (RCC) of which ﬁve
underwent nephrectomy. Three lesions demonstrated no enhancement.
Only in one case was a lesion felt to be equivocal necessitating further
imaging. Two cases were post-cryotherapy ablation, of which one
demonstrated recurrence not accessible on CECT. CEUS aided clinical
decision-making in 90% (19/21) of cases.
Conclusion: CEUS is an important adjunct to conventional imaging in
delineating the nature of complex renal lesions, particularly those with
renal impairment, when contrast agents are contra-indicated.
0797: THE IMPORTANCE OF THE BIOPSY OF NORMAL APPEARING
BLADDER MUCOSA AT THE EDGE OF PRIMARY TUMOUR RESECTION
SITE
Asheesh Kaul, Chris Jacobs, Michal Sut, Aasem Chaudry. Bedford Hospital
NHS Trust, Bedford, UK
Introduction: European Association of Urology guidelines advocate
separate biopsy of tumour base and edge during initial transurethral
resection of bladder tumour (TURBT). Most evidence available analyse the
prognostic value of random bladder biopsies rather than edge of resection
site speciﬁcally.
Aim: To evaluate the incidence and signiﬁcance of positive tumour edge
biopsies at primary TURBT.
Methods: 22 cases of primary TURBT performed between October 2010
and October 2011 were retrospectively reviewed. All resections included
a routine cold-cup biopsy of macroscopically normal mucosa at the
resection edge. Data sources included histopathology reports and Multi-
disciplinary Team Meeting notes.
Results: Abnormal biopsy was found in 9 patients (41%). Carcinoma-in-
situ (CIS) was found in 7 patients (32%) and in 2 cases (9%) biopsy results
were corresponding with primary pathology indicating incomplete
tumour resection.
Tumour edge biopsy effected management of 3 cases (22%). 2 patients (9%)
with CIS received intravesical chemotherapy with Bacillus Calmette-Gue-
rin (BCG) vaccine and 1 patient with incomplete resection underwent early
check cystoscopy and biopsy within 3 weeks of primary resection. Those
patients would otherwise have been scheduled for check cystoscopy at 3
months.
